Seenu M. Hariprasad, MD - Talking About Treatment Failure in nAMD: Practical Strategies for Switching VEGF-Targeted Therapies

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 2AM EDT 5 min · 24 Sep 2026 · NPR News Now

Entertainment Catch-Up: Presley Gerber, Phones in Theatres and Channing Tatum's Troll Account(?) 39 min · 24 Sep 2026 · Catch Up with Louise McSharry

2AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

How To Naturally Lift & Sculpt Your Face, Define Your Jawline & Age Better Without Injectables 1h 3m · 24 Sep 2026 · The Bossticks

Cómo dejar ir a alguien que todavía amas | Jueves de Lety & Ash | Episodio 697 22 min · 24 Sep 2026 · Se Regalan Dudas

Dead Internet 2026: DARPA, Peter Thiel, Alien AI & Memetic Magick 1h 47m · 24 Sep 2026 · Occult Symbolism and Pop Culture with Isaac Weishaupt

Report any issue

Source

Recorded02 Dec 2022

Publisherc.answersincme.com ↗

Handlerec:10296391

Show notes

Please visit answersincme.com/RUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for using intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in